Aera Therapeutics is a technology company.
Aera Therapeutics has raised $190.0M across 1 funding round.
Aera Therapeutics has raised $190.0M in total across 1 funding round.
Aera Therapeutics has raised $190.0M in total across 1 funding round.
Aera Therapeutics's investors include Accel, ARCH Venture Partners, Arrive, F-Prime Capital Partners, GV, K9 Ventures, Lux Capital, Soffinova Partners, SR One, Upfront Ventures.
Aera Therapeutics is a Boston-based biotechnology company developing proprietary delivery platforms for genetic medicines, addressing the key challenge of effective delivery to expand their use across therapeutic modalities and disease areas.[1][2][3][4] It builds protein nanoparticle (PNP) and targeted lipid nanoparticle (tLNP) platforms, plus antibody oligonucleotide conjugates (AOCs), based on endogenous human proteins to package and deliver nucleic acids more efficiently than current technologies; it also licenses compact, programmable gene editing enzymes.[1][2][4] Aera serves patients with unmet needs in various diseases by enabling next-generation genetic therapies, solving limitations in tissue targeting and delivery that restrict today's options.[1][3][5] Launched in February 2023 with $193 million in combined Series A and B financing led by ARCH Venture Partners, GV, and Lux Capital, the company shows strong early momentum through its distinguished scientific team and rapid platform advancement.[2][4]
Aera Therapeutics emerged from research in the lab of scientific founder Feng Zhang, Ph.D., a core member of the Broad Institute of MIT and Harvard, McGovern Institute investigator, James and Patricia Poitras Professor of Neuroscience at MIT, and Howard Hughes Medical Institute investigator, focusing on novel endogenous human proteins from retroelements that self-assemble into capsid-like structures for nucleic acid delivery.[4] Founded in 2022–2023 by a team of scientists, investors, and company builders, including CEO Akin Akinc (with nearly two decades at Alnylam Pharmaceuticals in R&D and commercial roles), the company launched publicly in February 2023 after securing $193 million in financing.[2][4][6] Early traction came from licensing Zhang's discoveries and assembling experts like Robert Dorkin (ex-Beam Therapeutics, leading PNP and LNP efforts) and others from Alnylam, Tessera, and AVROBIO, enabling quick platform development.[4][6] This biotech pedigree provided a pivotal foundation, humanizing Aera as a mission-driven effort to democratize genetic medicines beyond liver-focused applications.[1][5]
Aera stands out in genetic medicine delivery through these key strengths:
Aera rides the genetic medicine revolution, fueled by CRISPR, base editing, and mRNA advances, where delivery bottlenecks limit adoption beyond liver diseases like those treated by approved therapies (e.g., from Alnylam).[1][4][6] Timing is ideal post-2023 launch amid surging investment in non-viral vectors—evidenced by its $193M raise—amid market forces like rising gene therapy demand (projected multi-billion market) and safety concerns with AAV vectors.[2][3] Favorable tailwinds include regulatory momentum for genetic meds and AI-driven protein engineering, positioning Aera to influence the ecosystem by enabling "off-the-shelf" platforms for partners, much like LNPs unlocked RNAi drugs.[1][5] As a Broad Institute spinout, it amplifies academic-to-commercial translation in Boston's biotech hub, potentially accelerating therapies for neurology, oncology, and rare diseases.[4][6]
Aera is poised to lead next-gen delivery with clinical milestones likely in 2026–2027, targeting IND filings for PNP or tLNP programs in high-need areas like neuromuscular or oncology.[1][4] Trends like compact editors and multi-tissue targeting will shape its path, with potential partnerships (e.g., big pharma for payloads) driving expansion beyond its $193M war chest.[2][3] Influence may evolve from platform enabler to full therapeutic developer, reshaping genetic medicine accessibility as delivery hurdles fall—echoing how Alnylam pioneered siRNA, but with broader reach.[6] Investors and patients stand to gain from this delivery unlock, fulfilling its launch promise to transform unmet needs.[1]
Aera Therapeutics has raised $190.0M across 1 funding round. Most recently, it raised $190.0M Series B in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $190.0M Series B | Accel, ARCH Venture Partners, Arrive, F-Prime Capital Partners, GV, K9 Ventures, Lux Capital, Soffinova Partners, SR One, Upfront Ventures |